FLT3

Inhibitory Selectivity
Catalog No.Inhibitor Name FLT3Other
A10996Cabozantinib
**
VEGFR2/KDR,c-Met,Kit
A10027Quizartinib
***
A11411Dovitinib
****
c-Kit,VEGFR3/FLT4,FGFR1
A10610Amuvatinib
*
c-Kit (D816H),PDGFRα (V561D)
A10887Tandutinib
*
c-Kit,PDGFRβ,CSF-1R
A11180TG101209
*
JAK2,RET,JAK3
A10508KW-2449
****
Abl (T315I),Abl,FGFR1
A10352ENMD-2076
***
RET,Aurora A,VEGFR3/FLT4
A10198Dovitinib Dilactic Acid
****
c-Kit,FGFR1,VEGFR3/FLT4
A12694Pacritinib
**
JAK2 (V617F),JAK2,TYK2
A12427TCS 359
*
A10352ENMD-2076 L-(*)-Tartaric acid
RET,Aurora A,VEGFR3/FLT4
A15904UNC2025
****
Mer
A14025AMG 925
****
CDK4,CDK1
A14214G-749
****
Mer,Aurora B,RET
A14156AZD2932
PDGFRβ,VEGFR-2,c-Kit
A10769R406
Syk
A12419Go6976
JAK2,PKCα,PKCβ1
A11962TG-02 (SB1317)
*
CDK2, JAK2
A14411Gilteritinib (ASP2215)
****
Axl
A15003AST 487
Ret, c-Kit, KDR, c-Abl
A15520Pexidartinib (PLX3397)
*
Kit, CSF-1R
A15548SU5614
A16248BPR1J-097
**

Notes:
1.Hover mouse over " * " to view the IC50 value.(A few compounds have proven potency but without published IC50 data.)
2.For more details about the compound, click on the product name of your interest.
3.The higher the number of " * " is, the more potent the inhibitor or activator is.
4."" refers to compounds which do inhibitory effects on the related isoform, but without specific value.



Items 1 to 25 of 27 total

per page
Page:
  1. 1
  2. 2

Set Descending Direction
Catalog No. Product Name Application Product Information
A10027 SALE

AC220 (Quizartinib)

FLT3 inhibitor
AC220 (Quizartinib) is a uniquely potent and selective FLT3 inhibitor with IC50 of 0.56 ± 0.3 nM and >10 mM for MC4-11 and A375, respectively.
A16246

AC710 Mesylate

FLT3/KIT/PDGFRα/PDGFRβ inhibitor
AC710 Mesylate is a potent, selective PDGFR-family kinases inhibitor with Kd values of 0.6 nM/1.0 nM/1.3 nM/1.0 nM for FLT3/KIT/PDGFRα/PDGFRβ respectively.
A14025

AMG-925

Dual FLT3/CDK4 inhibitor
AMG-925 is a potent, selective, and bioavailable FLT3/cyclin-dependent kinase 4 (CDK4) dual kinase inhibitor.
A15003

AST 487

RET kinase inhibitor
AST487 is a Ret kinase inhibitor/FLT3 inhibitor with IC50 of 0.88 uM for Ret.
A14156

AZD 2932

mutil-targeted protein tyrosine kinase inhibitor
AZD2932 is a potent and mutil-targeted protein tyrosine kinase inhibitor with IC50 of 8 nM, 4 nM, 7 nM, and 9 nM for VEGFR-2, PDGFRβ, Flt-3, and c-Kit, respectively.
A16248

BPR1J-097

FLT3 inhibitor
BPR1J-097 is a novel small molecule FLT-3 inhibitor with promising in vivo anti-tumour activities.
A11411 SALE

Dovitinib (TKI-258)

RTK inhibitor
Dovitinib is a small-molecule multitargeted receptor tyrosine kinase inhibitor, which inhibits Ba/F3 cells transformed to IL3 independence by ZNF198-FGFR1 or BCR-FGFR1 with IC50 values of 150 nM and 90 nM, respectively.
A10198 SALE

Dovitinib Dilactic acid (TKI258 Dilactic acid)

RTK inhibitor
Dovitinib is a small-molecule multitargeted receptor tyrosine kinase inhibitor, which inhibits Ba/F3 cells transformed to IL3 independence by ZNF198-FGFR1 or BCR-FGFR1 with IC50 values of 150 nM and 90 nM, respectively.
A10352 SALE

ENMD-2076

Aurora Inhibitor
ENMD-2076 is a novel, orally-active antimitotic and antiangiogenic molecule inhibits Aurora A as well as tyrosine kinases that drive tumor vascularization, including VEGFR2 (KDR), PDGFR and the FGF receptors.
A16249

FLT3-IN-1

FLT3 inhibitor
FLT3-IN-1 is a novel potent and selective Flt3 inhibitor with IC50 of 10 nM; against FLT3-ITD-expressing MV4-11 cells with IC50 of 6 nM.
A16250

FLT3-IN-2

FLT3 inhibitor
FLT3-IN-2 is potent FLT3 inhibitor.
A14214

G-749

FLT3 inhibitor
G-749 is a novel and potent FLT3 inhibitor with IC50 of 0.4 nM, 0.6 nM and 1 nM for FLT3 (WT), FLT3 (D835Y).
A14411

Gilteritinib (ASP2215)

FLT/Axl inhibitor
Gilteritinib is a potent FLT3/AXL inhibitor, which showed potent antileukemic activity against AML with either or both FLT3-ITD and FLT3-D835 mutations.
A12419

Go 6976

PKC inhibitor
Go 6976 is a potent protein kinase C (PKC) inhibitor (IC50 = 7.9 nM).
A10508 SALE

KW-2449

Aurora Inhibitor
KW-2449 is a multikinase inhibitor of FLT3, ABL, ABL-T315I, and Aurora kinase.
A11753

MK-2461

c-Met Inhibitor
MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor.
A10610

MP470 (MP-470, Amuvatinib)

RTK inhibitor
MP470 is a c-Kit/PDGFR tyrosine kinase inhibitor.
A12694 SALE

Pacritinib (SB1518)

JAK2/FLT3 inhibitor
Pacritinib, also known as SB1518, is an orally bioavailable inhibitor of Janus kinase 2 (JAK2) and the JAK2 mutant JAK2V617F with potential antineoplastic activity. Pacritinib competes with JAK2 for ATP binding, which may result in inhibition of JAK2 activation, inhibition of the JAK-STAT signaling pathway, and so caspase-dependent apoptosis.
A15520 SALE

Pexidartinib (PLX3397)

CSF1/Kit/FLT3 inhibitor
Pexidartinib is a small-molecule receptor tyrosine kinase (RTK) inhibitor of KIT, CSF1R and FLT3 with potential antineoplastic activity.
A10769 SALE

R406 besylate

Syk Inhibitor
R406 is an orally available spleen tyrosine kinase inhibitor with an IC50 of 41 nM.
A15548 SALE

SU5614

FLT3 inhibitor
SU5614 is a potent and selective FLT3 inhibitor. SU5614 reverts the antiapoptotic and pro-proliferative activity of FLT3 ligand (FL) in FL-dependent cells.
A10887 SALE

Tandutinib (MLN518)

FLT-3 Inhibitor
Tandutinib (MLN518) inhibits the autophosphorylation of FLT3, c-KIT and PDGF receptor tyrosine kinases, thereby inhibiting cellular proliferation and inducing apoptosis.
A12427

TCS 359

-
TCS 359 is a potent inhibitor of FLT3 receptor tyrosine kinase (IC50 = 42 nM) that displays selectivity over a range of other kinases.
A11962 SALE

TG-02 (SB1317)

FLT3 inhibitor
TG-02 is a novel small molecule potent CDK/JAK2/FLT3 inhibitor.
A11180

TG101209

JAK2 inhibitor

TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells.

Items 1 to 25 of 27 total

per page
Page:
  1. 1
  2. 2

Set Descending Direction